TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effectiveness of Personalized Stroke Risk Communication - A Pilot Randomized Controlled Trial
Brief Summary: The goal of this research is to improve communication to Veterans. The investigators want to improve how doctors and nurses talk to patients about the risk of heart attack and stroke. The investigators will give everyone in the study information about the risk for heart attack or stroke. The investigators will also provide information on how to reduce this risk. This information will be given in one of two ways. The investigators want to see which way of giving information works better for veterans. The investigators also want to assess the impact of personalized stroke risk communication to patients at risk for stroke on patient knowledge, beliefs, and preferences for risk reduction behaviors and evaluate the impact of personalized risk communication on medication adherence and blood pressure. The investigators plan to enroll approximately 100 veterans for this study. All veterans will be from the Durham VA Primary Care Clinics. The investigators will ask everyone to be in the study for 3 months.


Options:
A: Intervention Type: BEHAVIORAL; Name: Pharmacist intervention; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Self-Management; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: attention control; Assigned to Arm(s): N/A
C: Arm Label: Personalized Risk Information; Type: ACTIVE_COMPARATOR; Interventions: Other: Personalized Heart Attack and Stroke Risk | Arm Label: Standard Education; Type: OTHER; Interventions: Other: Standard Education | Intervention Type: OTHER; Name: Personalized Heart Attack and Stroke Risk; Assigned to Arm(s): Personalized Risk Information | Intervention Type: OTHER; Name: Standard Education; Assigned to Arm(s): Standard Education
D: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Unit of use medication packaging, Behavioral: Mailed reminders to patient when medication refills are due, Behavioral: Note to Mental Health Provider when refill is overdue, Procedure: Aligning all prescriptions to fall due on same date | Intervention Type: BEHAVIORAL; Name: Unit of use medication packaging; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Mailed reminders to patient when medication refills are due; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Note to Mental Health Provider when refill is overdue; Assigned to Arm(s): Arm 1 | Intervention Type: PROCEDURE; Name: Aligning all prescriptions to fall due on same date; Assigned to Arm(s): Arm 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Brief Summary: The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to the first clinical failure event.


Options:
A: Arm Label: Combination ambrisentan + tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: ambrisentan, Drug: tadalafil | Arm Label: Monotherapy ambrisentan; Type: ACTIVE_COMPARATOR; Interventions: Drug: ambrisentan | Arm Label: Monotherapy tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: ambrisentan; Assigned to Arm(s): Combination ambrisentan + tadalafil, Monotherapy ambrisentan | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): Combination ambrisentan + tadalafil, Monotherapy tadalafil
B: Arm Label: Sildenafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sildenafil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Sildenafil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 20 mg tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 40 mg tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 20 mg tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 40 mg tadalafil
D: Intervention Type: DRUG; Name: Bosentan and Sildenafil; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Brief Summary: The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to the first clinical failure event.


Options:
A: Arm Label: Bosentan; Type: EXPERIMENTAL; Interventions: Drug: Bosentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Combination ambrisentan + tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: ambrisentan, Drug: tadalafil | Arm Label: Monotherapy ambrisentan; Type: ACTIVE_COMPARATOR; Interventions: Drug: ambrisentan | Arm Label: Monotherapy tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: ambrisentan; Assigned to Arm(s): Combination ambrisentan + tadalafil, Monotherapy ambrisentan | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): Combination ambrisentan + tadalafil, Monotherapy tadalafil
D: Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
Brief Summary: Autism spectrum disorders affect as many as 1 out of 150 children and are related to significant impairment in social, adaptive, and school functioning. Co-occurring conditions, such as anxiety, are common and may cause substantial distress and impairment beyond that caused by the autism diagnosis. Although effective interventions have been developed for typically developing youth with anxiety disorders, this approach needs to be adapted for children with autism. Accordingly, we are proposing a randomized controlled trial to examine the effectiveness of CBT relative to treatment as usual (TAU) in 46 youth ages 7-11 with autism spectrum disorders and comorbid anxiety disorder(s).


Options:
A: Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment As Usual | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Treatment As Usual; Assigned to Arm(s): Treatment as usual
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: family based cognitive behavior therapy | Intervention Type: BEHAVIORAL; Name: family based cognitive behavior therapy; Assigned to Arm(s): 2
C: Arm Label: Cognitive-behavioral therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral therapy | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral therapy; Assigned to Arm(s): Cognitive-behavioral therapy | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Group CBT for children | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Group CBT for children plus parent training | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group CBT for children; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Group CBT for children plus parent training; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Child System and Treatment Enhancement Projects (Child STEPs); The Clinic Treatment Project - Phase II
Brief Summary: The Clinic Treatment Project tested two alternative methods of delivering evidence-based practices within public community-based mental health clinics, using training and supervision procedures designed for the settings and users.


Options:
A: Arm Label: Usual Care Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: psychotherapy | Arm Label: Standard Manual Treatment (SMT); Type: EXPERIMENTAL; Interventions: Behavioral: evidence-based treatment | Arm Label: Modular Maual Treatment (MMT); Type: EXPERIMENTAL; Interventions: Behavioral: modular evidence-based treatment | Intervention Type: BEHAVIORAL; Name: psychotherapy; Assigned to Arm(s): Usual Care Treatment | Intervention Type: BEHAVIORAL; Name: evidence-based treatment; Assigned to Arm(s): Standard Manual Treatment (SMT) | Intervention Type: BEHAVIORAL; Name: modular evidence-based treatment; Assigned to Arm(s): Modular Maual Treatment (MMT)
B: Arm Label: Sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline (SRT) | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: SRT + CBT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline (SRT), Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sertraline (SRT); Assigned to Arm(s): SRT + CBT, Sertraline | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): CBT, SRT + CBT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral therapy | Arm Label: Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral therapy; Assigned to Arm(s): Cognitive Behavioral Therapy
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: family based cognitive behavior therapy | Intervention Type: BEHAVIORAL; Name: family based cognitive behavior therapy; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Child System and Treatment Enhancement Projects (Child STEPs); The Clinic Treatment Project - Phase II
Brief Summary: The Clinic Treatment Project tested two alternative methods of delivering evidence-based practices within public community-based mental health clinics, using training and supervision procedures designed for the settings and users.


Options:
A: Arm Label: Social Effectiveness Therapy for Children; Type: EXPERIMENTAL; Interventions: Behavioral: Social Effectiveness Therapy for Children (SET-C) | Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Pill placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pill Placebo | Intervention Type: BEHAVIORAL; Name: Social Effectiveness Therapy for Children (SET-C); Assigned to Arm(s): Social Effectiveness Therapy for Children | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Pill Placebo; Assigned to Arm(s): Pill placebo
B: Arm Label: Usual Care Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: psychotherapy | Arm Label: Standard Manual Treatment (SMT); Type: EXPERIMENTAL; Interventions: Behavioral: evidence-based treatment | Arm Label: Modular Maual Treatment (MMT); Type: EXPERIMENTAL; Interventions: Behavioral: modular evidence-based treatment | Intervention Type: BEHAVIORAL; Name: psychotherapy; Assigned to Arm(s): Usual Care Treatment | Intervention Type: BEHAVIORAL; Name: evidence-based treatment; Assigned to Arm(s): Standard Manual Treatment (SMT) | Intervention Type: BEHAVIORAL; Name: modular evidence-based treatment; Assigned to Arm(s): Modular Maual Treatment (MMT)
C: Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment As Usual | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Treatment As Usual; Assigned to Arm(s): Treatment as usual
D: Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Coping Cat cognitive-behavioral therapy for anxious youth | Arm Label: Waitlist Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coping Cat cognitive-behavioral therapy for anxious youth; Assigned to Arm(s): CBT

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Cardiac Protective Effect of Simvastatin on Cardiac Surgery: a Double Blind, Randomised Clinical Trial
Brief Summary: It is well know that statins have been used to low cholesterol to prevent and treat coronary artery disease for many years. It was also reported that statins could protect endothelial function and cardiac function during coronary artery bypass graft. However, some results were controversial. Also, there is no clinical data available on statin cardiac protection during surgery in China where rheumatic heart disease is prevalent. Thus, the investigators are trying to see whether statins can protect heart injury during cardiac surgery in Chinese. Part of patients will receive statin treatment and part of will not before surgery in the study. Both patients' heart function will be measured and compared after surgery to determine whether statins can protect heart injury during heart surgery.


Options:
A: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin | Arm Label: untreated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): treatment
B: Arm Label: CytoSorb; Type: EXPERIMENTAL; Interventions: Device: CytoSorb | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: CytoSorb; Assigned to Arm(s): CytoSorb
C: Arm Label: HOE 140; Type: EXPERIMENTAL; Interventions: Drug: HOE 140 | Arm Label: Aminocaproic Acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminocaproic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: HOE 140; Assigned to Arm(s): HOE 140 | Intervention Type: DRUG; Name: Aminocaproic Acid; Assigned to Arm(s): Aminocaproic Acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Interventional group; Type: EXPERIMENTAL; Interventions: Device: hemoadsorber for removal of cytokines | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: hemoadsorber for removal of cytokines; Assigned to Arm(s): Interventional group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Cardiac Protective Effect of Simvastatin on Cardiac Surgery: a Double Blind, Randomised Clinical Trial
Brief Summary: It is well know that statins have been used to low cholesterol to prevent and treat coronary artery disease for many years. It was also reported that statins could protect endothelial function and cardiac function during coronary artery bypass graft. However, some results were controversial. Also, there is no clinical data available on statin cardiac protection during surgery in China where rheumatic heart disease is prevalent. Thus, the investigators are trying to see whether statins can protect heart injury during cardiac surgery in Chinese. Part of patients will receive statin treatment and part of will not before surgery in the study. Both patients' heart function will be measured and compared after surgery to determine whether statins can protect heart injury during heart surgery.


Options:
A: Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
B: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin | Arm Label: untreated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): treatment
C: Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
D: Arm Label: High dose Atorvastatin 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Control, High dose Atorvastatin 80 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Cardiac Protective Effect of Simvastatin on Cardiac Surgery: a Double Blind, Randomised Clinical Trial
Brief Summary: It is well know that statins have been used to low cholesterol to prevent and treat coronary artery disease for many years. It was also reported that statins could protect endothelial function and cardiac function during coronary artery bypass graft. However, some results were controversial. Also, there is no clinical data available on statin cardiac protection during surgery in China where rheumatic heart disease is prevalent. Thus, the investigators are trying to see whether statins can protect heart injury during cardiac surgery in Chinese. Part of patients will receive statin treatment and part of will not before surgery in the study. Both patients' heart function will be measured and compared after surgery to determine whether statins can protect heart injury during heart surgery.


Options:
A: Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: statin; Type: EXPERIMENTAL; Interventions: Drug: atorvastatin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): statin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin | Arm Label: untreated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Dydrogesterone Versus Vaginal Progesterone Gel in the Luteal Phase Support: Randomized Controlled Trial
Brief Summary: The purpose of this study is to compare efficacy and tolerability of the dydrogesterone and the vaginal progesterone, used for luteal phase support.

(Initial start date was January 2009 but not for patients' recruitment only for paper work, documents, team organization, statistical pre-work actions and to gain the official approval of Institutional Review Board. The recruitment started in October 2010 and continued until October 2013.)


Options:
A: Arm Label: Subcutaneous progesterone; Type: EXPERIMENTAL; Interventions: Drug: Subcutaneous progesterone | Arm Label: Vaginal Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vaginal progesterone | Intervention Type: DRUG; Name: Subcutaneous progesterone; Assigned to Arm(s): Subcutaneous progesterone | Intervention Type: DRUG; Name: Vaginal progesterone; Assigned to Arm(s): Vaginal Progesterone
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: triptorelin acetate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Na Cl %0.9 | Intervention Type: DRUG; Name: triptorelin acetate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Na Cl %0.9; Assigned to Arm(s): 2
C: Arm Label: Oral dydrogesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral dydrogesterone | Arm Label: Crinone 8% vaginal gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crinone 8% gel | Intervention Type: DRUG; Name: Oral dydrogesterone; Assigned to Arm(s): Oral dydrogesterone | Intervention Type: DRUG; Name: Crinone 8% gel; Assigned to Arm(s): Crinone 8% vaginal gel
D: Arm Label: Progesterone SC; Type: EXPERIMENTAL; Interventions: Drug: Progesterone | Arm Label: Progesterone Tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone SC | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone Tablets

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Dydrogesterone Versus Vaginal Progesterone Gel in the Luteal Phase Support: Randomized Controlled Trial
Brief Summary: The purpose of this study is to compare efficacy and tolerability of the dydrogesterone and the vaginal progesterone, used for luteal phase support.

(Initial start date was January 2009 but not for patients' recruitment only for paper work, documents, team organization, statistical pre-work actions and to gain the official approval of Institutional Review Board. The recruitment started in October 2010 and continued until October 2013.)


Options:
A: Arm Label: Oral dydrogesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral dydrogesterone | Arm Label: Crinone 8% vaginal gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crinone 8% gel | Intervention Type: DRUG; Name: Oral dydrogesterone; Assigned to Arm(s): Oral dydrogesterone | Intervention Type: DRUG; Name: Crinone 8% gel; Assigned to Arm(s): Crinone 8% vaginal gel
B: Arm Label: Lipoic acid; Type: EXPERIMENTAL; Interventions: Device: Lipoic acid | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DEVICE; Name: Lipoic acid; Assigned to Arm(s): Lipoic acid | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone
C: Arm Label: Vaginal progesterone group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Arm Label: No progesterone group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Vaginal progesterone group
D: Arm Label: Dydrogesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dydrogesterone | Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dydrogesterone; Assigned to Arm(s): Dydrogesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo pill

Answer: A